Most roads led to India in 2020 when it came to deals to expand access to COVID-19 therapies, but the challenging year also saw significant private equity interest and there are expectations of more action ahead in the new year.

Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.

Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.

Strides and Shasun have seen an opportunity to grow as a single combined unit. The match is a no-brainer – Strides needs scale to make a global splash after selling Agila last year, while Shasun requires management bandwidth to pull it out of sagging prospects in APIs and CRAMS.